Guidelines for Systemic Treatment of Patients With Atopic Dermatitis at the University Clinic for Dermatology in Skopje
Year: 2025
Type: article
Abstract: This Guideline was developed for the needs of the University Clinic (UC) for Dermatology in Skopje and is based on the European Guidelines for the Systemic Therapy of Atopic Dermatitis (AD) from 2020 and 2021 (EuroGuiDerm Guideline). Dermatologists from the UC for Dermatology with extensive experience in pediatric dermatology and treating patients with AD participated in the process. The Guideline was adopted by the Expert Board of the UC for Dermatovenerology in Skopje in February 2025. This part of the Guideline contains general information about the goals and scope, the health issues covered in the Guideline, the target groups, and a methodology section. The Guideline provides guidelines for identifying patients who should be treated with systemic therapy and recommendations and information for each systemic drug. In addition, the Guideline provides recommendations and information on each systemic drug. The first section describes systemic treatment options, such as conventional immunosuppressive drugs (azathioprine, cyclosporine, glucocorticosteroids, methotrexate, and mycophenolate mofetil), biologic agents (dupilumab, lebrikizumab, nemolizumab, omalizumab, and tralokinumab) and Janus kinase inhibitors (abrocitinib, baricitinib, and upadacitinib).
Source: Academic Medical Journal
DOI: 10.53582/amj255117n
Institution: Ss. Cyril and Methodius University in Skopje
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4411577486